A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)

NCT06709417 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

DRUG: Sintilimab
DRUG: Chemotherapy
RADIATION: radiotherapy

Sponsor

Shanghai Chest Hospital